Internet-based Behavior Therapy for Adults With Tourette Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Exposure with response prevention, Brief psychoeducation with general psychological support.
- Who it may be relevant to
- Registry conditions: Tourette Syndrome, Chronic Tic Disorder. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Sweden
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Parallel-group, Randomized Controlled Trial of Internet-based Behavior Therapy for Adults With Tourette Syndrome
Overview
This study protocol outlines a parallel-group, randomized controlled trial (RCT) designed to evaluate the effectiveness of Internet-delivered behavior therapy (BT) based on exposure with response prevention (ERP) for adults with Tourette syndrome (TS) or chronic tic disorder (CTD). The primary aim is to evaluate the effects of Internet-delivered ERP-based BT on tic severity compared to a control condition offering general psychological support at week 11 counting from the treatment start. The primary outcome measure is the Yale Global Tic Severity Scale - Total Tic Severity subscale (YGTSS-TTS). Secondary outcomes include measures of tics-related impairment, work and social adjustment, rates of responders, self-rated tic severity, symptoms of depression, and quality of life. Long-term maintenance of results will be assessed at week 23 and 14 months after the treatment start. Participants will be recruited nationwide. The intervention group will receive 10 weeks of ERP-based therapy delivered through an online platform, with therapist support. The control group will receive psychoeducational content and general psychological support. Adherence to treatment, adverse events, and patient safety will be closely monitored throughout the trial. The study population will be intent-to-treat and the between-group differences at the primary endpoint will be assessed using an analysis of covariance (ANCOVA) with pre-score of the measure as covariate. A health-economic evaluation will assess the cost-effectiveness of the intervention.
Interventions
- Behavioral Exposure with response prevention
The central component of the intervention will be ERP. During the treatment, participants will receive information about tics and how to work with ERP. Continuously throughout the treatment patients will work with exposing themselves to situations that trigger their premonitory urges and practice suppressing their tics. They will learn different strategies to provoke their premonitory urges to make suppression of their tics more challenging and gradually increase the time they can suppress the t - Behavioral Brief psychoeducation with general psychological support
Participants who are randomized to the control group will receive access to brief psychoeducational content in the platform in combination with general psychological support from a therapist. No active BT components (BT, Habit Reversal Training, applied relaxation) are provided to the participants in the control group. The therapists will welcome the patients to the treatment, encourage them to engage in the treatment content and reach out to the therapist if they have any questions. Thereafter,
Primary outcome measures
- Yale Global Tic Severity Scale - Total Tic Severity subscale (YGTSS-TTS) [Time frame: Baseline, week 11 (primary end-point), 23 and 14 months after the treatment start.]
Secondary outcome measures (8)
- Yale Global Tic Severity Scale (YGTSS) - impairment scale [Time frame: Baseline, week 11 (primary end-point), 23 and 14 months after the treatment start.]
- Clinical Global Impression (CGI) [Time frame: Baseline, week 11 (primary end-point), 23 and 14 months after the treatment start.]
- Gilles de la Tourette Syndrome Quality of Life Scale (QTS-QoL) [Time frame: Baseline, week 11 (primary end-point), 23 and 14 months after the treatment start.]
- Montgomery-Asberg Depression Rating Scale (MADRS) [Time frame: Baseline, week 3, 7, 11 (primary end-point), 23 and 14 months after the treatment start.]
- Adult Tic Questionnaire (ATQ) [Time frame: Baseline, week 2-10, week 11 (primary end-point), week 23 and 14 months after the treatment start.]
- Work and social adjustment scale (WSAS) [Time frame: Baseline, week 2-10, week 11 (primary end-point), week 23 and 14 months after the treatment start.]
- Treatment Inventory of Costs in Psychiatric Patients (TIC-P) [Time frame: Baseline, week 11 (primary end-point), 23 and 14 months after the treatment start.]
- Assessing Quality of Life 6 Dimensions (AQoL-6D) [Time frame: Baseline, week 11 (primary end-point), 23 and 14 months after the treatment start.]
Eligibility criteria
Inclusion criteria
≥ 18 years of age.
Primary diagnosis of TS/CTD, according to criteria in Diagnostic and Statistical Manual of mental disorders 5th edition.
Provided digital informed consent.
Have a Total Tic Severity Score (TTS) of >15, or >10 for individuals with motor or vocal tics only, in the past week, as measured by the Yale Global Tic Severity Scale (YGTSS).
Being willing and able to follow the study procedures and participate in the 10-week treatment program.
Being fluent in Swedish.
Have regular access to a computer connected to the Internet, sufficient technical skills to use the treatment platform, as well as a mobile phone to receive text messages.
Exclusion criteria
Ongoing or planned psychological treatment for TS/CTD.
Previous BT for tics of a minimum of 8 sessions with a qualified therapist within 12 months prior to assessment.
Adjustment of medication for tics within the last two months prior to assessment.
Severe psychiatric comorbidities such as organic brain disorders, bipolar disorder, ongoing psychosis, anorexia nervosa or substance use disorders that can interfere with the treatment for TS/CTD.
Acute psychiatric problems such as severe depression or suicidal risk needing immediate psychiatric care.
Severe tics causing immediate risk to the participants themselves or to others and requiring urgent medical attention.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Sweden · 1 center
- Karolinska Institutet — Stockholm
Publications
- Sannemalm M, Lybert N, Gunnarsson L, Andren P, Kraepelien M, Bragesjo M, Fondberg R, Ivanov VZ, Mataix-Cols D, Fernandez de la Cruz L, Andersson E, Ruck C, Ivanova E. Study protocol for a parallel-group randomized controlled trial of internet-delivered behavior therapy for adults with Tourette syndrome. Front Digit Health. 2025 Aug 29;7:1518666. doi: 10.3389/fdgth.2025.1518666. eCollection 2025. PMID 40949315
Identifiers
NCT: NCT06271083 · 2023-06541-01